Moderna Inc (MRNA) Stock: A Closer Look at the Analyst Ratings
Additionally, the 36-month beta value for MRNA is 1.62. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0
Additionally, the 36-month beta value for MRNA is 1.62. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0
In the past week, MRNA stock has gone down by -6.89%, with a monthly gain of 14.40% and a quarterly surge of 21.42%. The volatility
Moderna Inc (NASDAQ: MRNA)’s stock price has gone rise by 10.36 in comparison to its previous close of 103.03, however, the company has experienced a
The stock of Moderna Inc (MRNA) has gone up by 2.11% for the week, with a -3.05% drop in the past month and a 23.55%
The 36-month beta value for MRNA is also noteworthy at 1.61. The public float for MRNA is 334.65M, and at present, short sellers hold a
The stock of Moderna Inc (MRNA) has seen a -2.26% decrease in the past week, with a -12.75% drop in the past month, and a
Moderna Inc (NASDAQ: MRNA) has experienced a rise in its stock price by 87.41 compared to its previous closing price of 129.39. However, the company
, and the 36-month beta value for MRNA is at 1.64. The public float for MRNA is 331.47M, and currently, shorts hold a 6.96% of
© 2024, Fueled by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.